We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00563953
First Posted: November 27, 2007
Last Update Posted: December 22, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Schering-Plough
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
  Purpose
This is a multicenter study of a primary chemotherapy regimen in breast cancer patients at risk of developing cardiotoxicity. The aim of the study is to evaluate the response rate at surgery.

Condition Intervention Phase
Breast Cancer Drug: Liposomal pegylated doxorubicine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multicenter Clinical Trial of Pegylated Liposomal Doxorubicin (Caelyx®) as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease or Age Over 65 Years.

Resource links provided by NLM:


Further study details as provided by SOLTI Breast Cancer Research Group:

Primary Outcome Measures:
  • Pathological complete response (pCR). pCR is defined as the absence of invasive cancer in the surgical breast specimen. This definition includes evidence of carcinoma in situ only. [ Time Frame: At surgery. ]

Secondary Outcome Measures:
  • Clinical response rate (complete plus partial responses). Clinical response will be assessed by imaging using the WHO criteria. [ Time Frame: Before and after treatment with paclitaxel. ]
  • Breast-conserving surgery: tumorectomy or quadrantectomy with or without lymphadenectomy versus mastectomy. [ Time Frame: At surgery. ]
  • Axillary node involvement after primary chemotherapy. [ Time Frame: At surgery. ]
  • Left ventricular ejection fraction measured by echocardiography or MUGA. [ Time Frame: At baseline, every 2 doxorubicine cycles and before surgery. ]
  • Cardiac sign/symptom questionnaire. [ Time Frame: At baseline, every 2 doxorubicine cycles and before surgery. ]
  • Relapse-free survival at 5 years after surgery and overall survival at 5 years after study entry. [ Time Frame: Until 5 years after surgery. ]

Enrollment: 50
Study Start Date: September 2007
Study Completion Date: August 2016
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Drug: Liposomal pegylated doxorubicine
Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Other Name: Caelyx

Detailed Description:

This is a phase II, uncontrolled, open label, multicenter study of a primary chemotherapy regimen consisting of four cycles of liposomal pegylated doxorubicine 35 mg/m² IV plus cyclophosphamide 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery in breast cancer patients at risk of developing anthracycline-induced cardiotoxicity.

Surgery (tumorectomy, quadrantectomy, or mastectomy plus lymphadenectomy) will be performed 2 to 5 weeks after the last primary chemotherapy infusion.

Patients with > 10% of hormone receptor-positive cells will receive appropriate hormone therapy according to menopausal status.

Patients treated with breast-conserving surgery will receive radiation therapy to the mammary gland.

Patients with T4 tumors or significant axillary involvement (≥ ypN2) will receive radiation therapy to the breast or chest wall and to the lymph node chains.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed invasive breast cancer (tumor > 2 cm).
  • Estrogen receptor-negative or -weakly positive tumors (less than 50% of cells), as evaluated using IHC.
  • Risk factors for developing anthracycline-induced cardiomyopathy.

Exclusion Criteria:

  • Severe heart failure (NYHA Class III or IV) .
  • Metastatic disease.
  • LVEF < 45%.
  • Pregnant or breast-feeding patients.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563953


Locations
Spain
Institut Català d'Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Son Llàtzer
Palma de Mallorca, Illes Balears, Spain, 07198
Hospital Universitario Sant Joan de Reus
Reus, Tarragona, Spain, 42301
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08025
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Universitari Arnau de Vilanova
Lleida, Spain, 25198
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital Universitario Morales Meseguer
Murcia, Spain, 30008
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Schering-Plough
Investigators
Study Chair: Miguel Gil, MD Institut Català d'Oncologia
  More Information

Publications:
Gil MJ, Bellet MC, Llombart, Ojeda B, Manso L, Mesia C, Morales S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, Baselga J. Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study. Cancer Research 71(24 Suppl.): 403s, 2011.(CTRC-AACR San Antonio Breast Cancer Symposium)
Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.

Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT00563953     History of Changes
Other Study ID Numbers: SOLTI0702
2007-001428-11 ( EudraCT Number )
First Submitted: November 26, 2007
First Posted: November 27, 2007
Last Update Posted: December 22, 2016
Last Verified: August 2016

Keywords provided by SOLTI Breast Cancer Research Group:
Breast
Cancer
Anthracyclines
Cardiopathy

Additional relevant MeSH terms:
Breast Neoplasms
Heart Diseases
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cardiovascular Diseases
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action


To Top